|
|
|
Reference:
1. Rivotril® clonazepam 0.5 mg and 2 mg tablets. Canada; 2018. https://www.rochecanada.com/PMs/Rivotril/Rivotril_PM_E.pdf
2. de Castro LA, Ribeiro-Rotta RF. The effect of clonazepam mouthwash on the symptomatology of burning mouth syndrome: an open pilot study. Pain Med 2014;15(12):2164-5.
3. Tan SN, Song E, Dong XD, Somvanshi RK, Cairns BE. Peripheral GABA-A receptor activation modulates rat tongue afferent mechanical sensitivity. Arch Oral Biol 2014;59:251-7.
4. Kuten-Shorrer M, Treister NS, Stock S, Kelley JM, Ji DY, Woo S-B, et al. Topical clonazepam solution for the management of burning mouth syndrome. Oral Abstract Proceedings of the Annual Meeting of the American Academy of Oral Medicine, Atlanta, GA, April 6-9, 2016. https://www.oooojournal.net/article/S2212-4403(16)30324-8/pdf
5. Besson M, Matthey A, Daali Y, Poncet A, Vuilleumier P, Curatolo M, et al. GABAergic modulation in central sensitization in humans: a randomized placebo-controlled pharmacokinetic-pharmacodynamic study comparing clobazam with clonazepam in healthy volunteers. Pain 2015;156:397-404.
Keywords:
-
